Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 273

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 273
---
, CSL additionally demanded interest and damages for lost profit, with an aggregate          
 demand amount of $1,476. The Company has disputed CSL’s payment demand and contends that CSL’s demands are baseless under                    
 the Framework Supply Agreement, as the minimum purchase commitment under the Framework Supply Agreement is conditional upon first            
 obtaining approval of the FDA and the European Medicines Evaluation Agency, or EMEA, and other quality and clinical milestones, none         
 of which has occurred. Notwithstanding, CSL claimed to have obtained a valid German court order in its favor and to endeavor to seek         
 for its enforcement in Israel. Company’s position is that CSL’s claim for the payment of the said unshipped minimum purchase                 
 commitments lacks any ground under the terms of the Framework Supply Agreement and, moreover, that the Company was never served with         
 German judicial documents (e.g., statement of claim) of CSL with translations in Hebrew, English or Arabic, as required under the            
 applicable German and international rules of proceeding. Consequently, based on advice of a German legal counsel, the Company are            
 in the opinion that the legal proceeding initiated by CSL suffered a fundamental and material procedural error and that no enforceable       
 German judgement could derive thereto. In 2024, the Company has initiated a proceeding in Germany to annul said German court’s               
 purported ruling. A hearing to annul the judgement in Germany is scheduled for April 2025 and a hearing to discuss the enforcement           
 in Israel is scheduled for June 2025. With respect to the hearing to annul the judgment, the judge requested that the parties submit         
 their arguments in writing. The Company submitted its arguments to the German court by way of a brief on April 11, 2025. In May 2025,        
 the German court issued a judgment dismissing the Company's annulment claim. On July 4, 2025, the Company entered into an agreement          
 with CSL pursuant to which the Company is required to make an immediate payment of $30 and an additional payment of $300, by the             
 Company to CSL subsequent to the closing of Company's initial public offering, as well as reimburse certain of CSL’s legal                   
 expenses and two future payments of $300 and $200 by the Company to CSL upon the achievement of certain global sales milestones. As a result 
 the Company recorded a provision of $430.                                                                                                    |

<div align='center'>F-23</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S